Rosnilimab — Overview
Rosnilimab is a first-in-class pathogenic T cell depleter engineered to restore immune homeostasis
By selectively targeting and depleting pathogenic T cells in the periphery and inflamed tissue, rosnilimab reduces T cell activity, B cell recruitment and plasma cell-mediated autoantibody secretion, while sparing naïve T cells to preserve overall immune function and restore immune homeostasis
Rosnilimab selectively targets pathogenic T cells in periphery and inflamed tissue to restore immune homeostasis
Effector T cells (Teff): activated T cells (cytotoxic, helper, Treg); Follicular/Peripheral Helper T cells (Tfh, Tph): support B cell differentiation and maturation.
To access scientific publications on this topic, please click here.